Immunogen
Synthesized peptide derived from human LLR1 AA range: 116-166
Specificity
This antibody detects endogenous levels of LLR1 at Human
Source
Polyclonal, Rabbit,IgG
Formulation
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Dilution rate
WB 1:500-2000
Purification process (Immunogen)
The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.
Background
The protein encoded by this gene contains a leucine-rich repeat (LRR). It specifically interacts with TNFRSF9/4-1BB, a member of the tumor necrosis factor receptor (TNFR) superfamily. Overexpression of this gene suppresses the activation of NF-kappa B induced by TNFRSF9 or TNF receptor-associated factor 2 (TRAF2), which suggests that this protein is a negative regulator of TNFRSF9-mediated signaling cascades. Alternative splicing results in multiple transcript variants.[provided by RefSeq, Feb 2011],
Function
function:May negatively regulate the 4-1BB-mediated signaling cascades which result in the activation of NK-kappaB and JNK1. Probable substrate recognition subunit of an ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.,pathway:Protein modification; protein ubiquitination.,similarity:Contains 5 LRR (leucine-rich) repeats.,subunit:Interacts with the cytoplasmic domain of TNFRSF9. Component of the probable ECS(PPIL5) E3 ubiquitin-protein ligase complex which contains CUL2, RBX1, Elongin BC complex and PPIL5. Interacts with CUL2, RBX1, TCEB1 and TCEB2.,tissue specificity:Ubiquitous. Maximal expression was seen in the heart and skeletal muscle and minimal expression seen in the kidney.,
Human protein sequence Database
Q96L50
Mouse protein sequence database
Rat protein sequence database
Tissue expression
Ubiquitous. Maximal expression was seen in the heart and skeletal muscle and minimal expression seen in the kidney.